posted on 2020-07-20, 13:34authored byThomas Cheviet, Sharon Wein, Gabriel Bourchenin, Manon Lagacherie, Christian Périgaud, Rachel Cerdan, Suzanne Peyrottes
Malaria is an infectious
disease caused by a parasite of the genus Plasmodium, and the emergence of parasites resistant to
all current antimalarial drugs highlights the urgency of having new
classes of molecules. We developed an effective method for the synthesis
of a series of β-modified acyclonucleoside phosphonate (ANP)
derivatives, using commercially available and inexpensive materials
(i.e., aspartic acid and purine heterocycles). Their biological evaluation
in cell culture experiments and SAR revealed that the compounds’
effectiveness depends on the presence of a hydroxyl group, the chain
length (four carbons), and the nature of the nucleobase (guanine).
The most active derivative inhibits the growth of Plasmodium
falciparum in vitro in the nanomolar range (IC50 = 74 nM) with high selectivity index (SI > 1350). This compound
also showed remarkable in vivo activity in P. berghei-infected mice (ED50 ∼ 0.5 mg/kg)
when administered by the ip route and is, although less efficient,
still active via the oral route. It is the first ANP derivative with
such potent antimalarial activity and therefore has considerable potential
for development as a new antimalarial drug.